Kigabeq (vigabatrin)

Kigabeq is indicated in infants and children from 1 month to less than 7 years of age for:

  • Treatment in monotherapy of infantile spasms (West's syndrome)
  • Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated.

Kigabeq is available as 100 mg and 500 mg soluble tablets.

Distribution

Alan Pharmaceuticals is the distributor for Kigabeq (vigabatrin) in the United Kingdom.


Diacomit (stiripentol) Product Information

The Patient Information Leaflet and Summary of Product Characteristics for Kigabeq (vigabatrin) can be accessed here.

The link will take you to the electronic Medicines Compendium (eMC) website which is a non-Alan Pharmaceuticals website. Alan Pharmaceuticals does not recommend, endorse or accept liability for sites controlled by third-parties.


European Public Assessment Report

Please see the European Public Assessment Report here.

This link will take you to the European Medicines Agency (EMA) website which is a non-Alan Pharmaceuticals website. Alan Pharmaceuticals does not recommend, endorse or accept liability for sites controlled by third-parties.

© Alan Pharmaceuticals 2025 ..l.. Modern Slavery Statement ..l.. Contact Us